Return to search results.
Complete title: Gilead GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen
|Research Study Number||20111441|
|Principal Investigator||Andrew Coveler, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Colon Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.